Ambu SARL is the French subsidiary of Danish medical device manufacturer Ambu A/S, which made its name with the Ambu bag, the world’s first self-inflating resuscitator, launched in 1956. It transformed emergency medical treatment at the time and Ambu is now synonymous with bag ventilators. Today, Ambu continues to focus on developing products that will make a difference to patients and doctors.
“Our continued goal is to improve the functionality and performance of everyday medical devices and thereby optimize workflow, reduce costs and improve patient care,” says Managing Director Sébastien Piat.
Ambu’s success in this area has brought it international growth and success. As well as the French market, Mr. Piat is also responsible for sales of Ambu products in the Benelux countries and North Africa. “We generate turnover of 31 million EUR – three times the result from just ten years ago – out of a group total of 350 million EUR,” he says.
Our specialism lies in the systematic adding of value to devices that are used every day in the medical setting.” Innovation is the main driver of this success and the uniqueness of its solutions. From single-use breathing bags Ambu has expanded its product range to cover single-use devices for airway management, endoscopy, cardiology and neurology.
"Our continued goal is to improve the functionality and performance of everyday medical devices and thereby optimize workflow, reduce costs and improve patient care." Sébastien PiatManaging Director
“One of the big problems in hospitals today are hospital-acquired infections and cross-contamination between patients,” explains Mr. Piat. “For example, studies have shown that even under the most stringent hygiene protocols, one in four reusable EEG electrodes are contaminated with bacteria. That is why many are switching to disposable EEG electrodes.”
Similarly, internal diagnostic and treatment equipment like endoscopes are a potential source of cross-contamination. Here, too, Ambu offers a single-use alternative.
“Treating hospital-acquired infections is swallowing an ever-growing proportion of healthcare budgets and resources,” says Mr. Piat. “Just as no one would now dream of using the same hypodermic needle twice, the trend is moving towards single-use solutions for all items that come into contact with patients.”
Single-use devices also speed up the treatment process – a key advantage in light of increased demand caused by an ageing population. “We are expecting strong growth in the coming years and have set a target of 50 million EUR in sales in France and the Benelux in the next three years,” says Mr. Piat. “Particularly in areas like endoscopy, we want to see a wholesale shift towards single-use devices with the aim of improving patient safety and reducing hospital infections.”